Results 321 to 330 of about 307,381 (359)
Some of the next articles are maybe not open access.
Immunogenetics of systemic sclerosis
Autoimmunity Reviews, 2011In the field of genetics of SSc, we are currently reaching a period of rapid data production. Several themes are already rising from the first wave of results. First, some genetic variants clearly predispose to multiple autoimmune diseases, thus providing evidence for a shared autoimmune genetic background.
P, Dieudé, C, Boileau, Y, Allanore
openaire +2 more sources
Treatment of systemic sclerosis
Current Opinion in Rheumatology, 1991Systemic sclerosis is an extremely variable disease in its manifestations and consequently, treatment needs to be individualized depending on the specific problems that each patient has. Limited scleroderma patients have a prolonged duration of Raynaud's phenomenon and puffy fingers before they develop any skin thickening, digital ulcers or ...
openaire +3 more sources
2009
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +2 more sources
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +2 more sources
Treatment of systemic sclerosis
Current Opinion in Rheumatology, 1993Guidelines for the conduct of clinical trials in progressive systemic sclerosis have been recommended to determine drug efficacy better. To date, the results of disease-modifying drugs in scleroderma have been disappointing. The treatment of esophagitis has been revolutionized by omeprazole.
openaire +3 more sources
Geoepidemiology of systemic sclerosis
Autoimmunity Reviews, 2010Systemic sclerosis (SSc) is a rare and potentially severe connective-tissue disease, characterized by skin fibrosis and involvement of internal organs. Because of its rarity and heterogeneous clinical presentation, reliable epidemiological studies on SSc have been particularly difficult to carry out. SSc prevalence is estimated between 3 and 24 per 100,
Brigitte, Ranque, Luc, Mouthon
openaire +2 more sources
Genetics of systemic sclerosis
Journal of Scleroderma and Related Disorders, 2020Systemic sclerosis is an autoimmune disease characterized by generalized fibrosis in connective tissues and internal organs as consequences of microvascular dysfunction and immune dysfunctions, which leads to premature death in affected individuals.
Yuki Ishikawa, Chikashi Terao
openaire +2 more sources
The fibroblast in systemic sclerosis
Clinics in Dermatology, 1994T he pathogenesis of the dramatic changes seen in systemic scleroderma is still poorly understood; however, three events are supposed to be involved: (1) alterations of the vessel wall, (2) immunologic changes, and (3) disturbance in the production of extracellular matrix proteins (for review see Ref 1).
S, Sollberg +3 more
openaire +2 more sources
Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology, 2014Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic.
Jingxiu, Xuan +3 more
openaire +2 more sources
SYSTEMIC SCLEROSIS (SCLERODERMA)
Acta Clinica Belgica, 2007Systemic sclerosis is a rare and often debilitating disorder characterized by a pathological triad: increased deposition of extracellular matrix and collagen in tissues, microvascular damage and dysfunction, and immune activation as evidenced by inflammation and frequent occurrence of autoantibodies.
Roufosse, Florence +1 more
openaire +2 more sources
Systemic Sclerosis, Scleroderma
2006Abstract The scleroderma spectrum of disorders includes several diseases that have Raynaud’s phenomenon or skin sclerosis in common, comprising (1) localized cutaneous scleroderma; (2) systemic sclerosis (SSc)—the most important form of scleroderma—limited cutaneous SSc, diffuse cutaneous SSc, and overlap syndromes (with features of ...
Christopher P. Denton, Carol M. Black
openaire +1 more source